Compare Jumia Technologies AG - ADR (JMIA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Smith & Nephew plc — how do they compare? Jumia Technologies AG - ADR trades at $6.27 (market cap $865.90M), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 12.8× Jumia Technologies AG - ADR's market cap, and Smith & Nephew plc pays a 2.95% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Smith & Nephew plc for 121 Days on average.
| JMIA | SNN | |
|---|---|---|
Market Cap | $865.90M | $11.10B |
Volume | 1,695,227 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $37.17 |
52-Week Low | $5.69 | $26.42 |
Typical Hold Time | 28 Days | 121 Days |
Enterprise Value | $831.54M | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $6.315, down 6.31% today, amid a bearish technical signal. The company reported revenue of $188.93M in 2025 with a net loss of $61.55M, though losses are narrowing year-over-year. Analyst consensus is bullish with a $12.00 price target, and recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
The outlook hinges on JMIA achieving profitability targets, with upside potential from analyst targets but risks from persistent losses and high valuation multiples. Execution on cost control and African e-commerce growth are critical for stock performance, while cash flow volatility remains a concern.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
